Susquehanna International Group, LLP Protara Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$1.96 - $4.14 $2,252 - $4,756	-1,149 Reduced 10.27%	10,036 $20,000
Q1 2024 May 07, 2024	BUY	$1.86 - $4.83 $20,804 - $54,023	11,185 New	11,185 $44,000
Q3 2023 Nov 14, 2023	BUY	$1.64 - $2.93 $57,352 - $102,465	34,971 New	34,971 $58,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $5.33 $6,244 - $11,885	2,230 Added 16.23%	15,969 $47,000
Q1 2022 May 16, 2022	SELL	$4.19 - $6.9 $59,175 - $97,448	-14,123 Reduced 50.69%	13,739 $70,000
Q4 2021 Feb 14, 2022	BUY	$6.15 - $7.76 $73,609 - $92,879	11,969 Added 75.31%	27,862 $188,000
Q3 2021 Nov 15, 2021	SELL	$6.38 - $9.3 $30,088 - $43,858	-4,716 Reduced 22.88%	15,893 $110,000
Q2 2021 Aug 11, 2021	BUY	$8.68 - $16.99 $178,886 - $350,146	20,609 New	20,609 $201,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $25.8M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.